Jeffrey P. Bruce

2.0k total citations
26 papers, 517 citations indexed

About

Jeffrey P. Bruce is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Jeffrey P. Bruce has authored 26 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cancer Research, 13 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Jeffrey P. Bruce's work include Cancer Genomics and Diagnostics (10 papers), Ovarian cancer diagnosis and treatment (5 papers) and PARP inhibition in cancer therapy (5 papers). Jeffrey P. Bruce is often cited by papers focused on Cancer Genomics and Diagnostics (10 papers), Ovarian cancer diagnosis and treatment (5 papers) and PARP inhibition in cancer therapy (5 papers). Jeffrey P. Bruce collaborates with scholars based in Canada, United States and United Kingdom. Jeffrey P. Bruce's co-authors include Trevor J. Pugh, Kwok Wai Lo, Chi Man Tsang, Vivian Wai Yan Lui, Fei‐Fei Liu, Wei Xu, Brian O’Sullivan, Scott V. Bratman, Kenneth W. Yip and Neesha C. Dhani and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Jeffrey P. Bruce

21 papers receiving 514 citations

Peers

Countries citing papers authored by Jeffrey P. Bruce

Since Specialization

Citations

This map shows the geographic impact of Jeffrey P. Bruce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey P. Bruce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey P. Bruce more than expected).

Fields of papers citing papers by Jeffrey P. Bruce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey P. Bruce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey P. Bruce. The network helps show where Jeffrey P. Bruce may publish in the future.

Co-authorship network of co-authors of Jeffrey P. Bruce

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey P. Bruce. A scholar is included among the top collaborators of Jeffrey P. Bruce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey P. Bruce. Jeffrey P. Bruce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Autophagy/lysosome disruption via pikfyve inhibition in multiple myeloma	Blood	Cecília Bonolo de Campos, Zhihua Li et al.	0
2	PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism	Blood	Cecília Bonolo de Campos, Zhihua Li et al.	1
3	T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab	Cell Reports	Xuan Li, Ben X. Wang et al.	0
4	Abstract 2060: Independent validation of endogenous retrotransposable elements as predictive biomarkers of immune checkpoint blockade response	Cancer Research	Sajid A. Marhon, Farnoosh Abbas‐Aghababazadeh et al.	0
5	An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for Cervical Cancer	Clinical Cancer Research	Melania Pintilie, Kathy Han et al.	4
6	Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns	Nature Communications	Derek Wong, Ping Luo et al.	3
7	Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma	Blood	Jenna Eagles, Arnavaz Danesh et al.	1
8	Germline whole genome sequencing in adults with multiple primary tumors	Familial Cancer	Qiliang Ding, Stephenie D. Prokopec et al.	0
9	Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases	Frontiers in Oncology	Corinne Serruya, Timothée Revil et al.	5
10	A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer	Clinical Cancer Research	Kathy Han, Anthony Fyles et al.	20
11	CD8+ Tumor-Infiltrating Lymphocyte Abundance Is a Positive Prognostic Indicator in Nasopharyngeal Cancer	Clinical Cancer Research	Wei Shi, Jeffrey P. Bruce et al.	7
12	AACR Project GENIE: 100,000 Cases and Beyond	Cancer Discovery	Trevor J. Pugh, Jeffrey P. Bruce et al.	49
13	Elevation in viral entry genes and innate immunity compromise underlying increased infectivity and severity of COVID-19 in cancer patients	Scientific Reports	Jennifer Kwan, Liang Lin et al.	7
14	EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression	Clinical Cancer Research	Stéphanie Lheureux, Ana Oaknin et al.	95
15	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer	Gynecologic Oncology	Ainhoa Madariaga, Swati Garg et al.	6
16	Translational genomics of nasopharyngeal cancer	Seminars in Cancer Biology	Chi Man Tsang, Vivian Wai Yan Lui et al.	98
17	Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient	Molecular Case Studies	Ilaria Colombo, Swati Garg et al.	8
18	Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial	British Journal of Cancer	Zachary Veitch, David W. Cescon et al.	45
19	Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma	Cell Reports	Christina Karamboulas, Jeffrey P. Bruce et al.	55
20	Abstract 1033: Patient-derived xenografts for prognostication and personalized treatment for head and neck squamous cell carcinoma	Cancer Research	Christina Karamboulas, Jeffrey P. Bruce et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact